BioBusiness

Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.

AstraZeneca, via its subsidiary Alexion Pharmaceuticals, will purchase a portfolio of preclinical rare disease gene therapies from Pfizer in a deal worth up to $1 billion.

The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025.

Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.

Roche will pay up to $2.8 billion for the rights to Alnylam’s RNA-based hypertension therapeutic.

Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.

MilliporeSigma has invested $25 million to expand its cell culture media production facility in Lenexa, Kan.

Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.

Under a global license agreement, Bristol Myers Squibb and Evotec will advance the development of neurodegeneration pipeline assets.

The proposed spin-off of Sandoz into an independent entity has been approved by Novartis’ board of directors.

The partnership will see Flagship and Pfizer work to create a new pipeline of innovative medicines.

The expanded deal, now potentially worth more than $1.2 billion, will work to develop in vivo therapies, including sickle cell disease.

Novartis’ acquisition of biotech company DTx Pharma boosts its neuroscience pipeline and expands its capabilities in RNA-based therapeutics.

The goal for Upperton is to become fully operational by Q4 of 2023 for development and non-GMP manufacturing and a target start of GMP operations in January 2024.

After the completion of the merger, the company is expected to operate under the name “Neurogene Inc."

Westlake’s third fund of $450 million will be used to grow early stage biotechnology companies.

German manufacturer metabion is conducting a multi-million euro expansion of its oligonucleotide manufacturing capacity in Munich East.

Start-ups are plagued with common issues that dramatically decrease their odds of achieving investor funding.

Exploring new fields can bring novel antibody candidates to the pipeline.

In addition, Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.

Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.

If we view a change opposite of one’s interest as antithetical to innovation, we risk losing sight of our ultimate goal.

The debate surrounding drug pricing changes rages on.

Donaldson Company’s €136 million (US$148 million) acquisition of Univercells is designed to broaden its portfolio of biomanufacturing solutions.